<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742221</url>
  </required_header>
  <id_info>
    <org_study_id>2012-002</org_study_id>
    <nct_id>NCT01742221</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure</brief_title>
  <official_title>A Phase 1b, Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neumedicines Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Neumedicines Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of
      HemaMax in healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, placebo-controlled, double-blind study of HemaMax to evaluate the safety,
      tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single 12 μg
      subcutaneous dose of HemaMax on 60 healthy subjects for 28 days after HemaMax administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of HemaMax in healthy subjects.</measure>
    <time_frame>3 months</time_frame>
    <description>Number of subjects with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics, pharmacodynamics and immunogenicity of HemaMax in healthy subjects</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate PK parameters AUC, Cmax, Tmax, t ½, Vz/F, and CL/F for HemaMax. To evaluate biological response parameters following HemaMax.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hematopoietic Syndrome Due to Acute Radiation Syndrome</condition>
  <arm_group>
    <arm_group_label>HemaMax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous 12 microgram dose of HemaMax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HemaMax</intervention_name>
    <description>single subcutaneous 12 microgram dose of HemaMax</description>
    <arm_group_label>HemaMax</arm_group_label>
    <other_name>rHuIL-12, NM-IL-12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single subcutaneous dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female subjects, who have signed the informed consent form must meet all of
             the following criteria

               1. 18 to 45 years of age

               2. Body mass index (BMI) &gt; 19 and &lt; 0 kg/m2

               3. Normal ECG, vital signs and laboratory test results

               4. Use of effective birth control method and abstinence from sex

               5. Negative pregnancy test and drug screen

        Exclusion Criteria:

          -  Subjects with any of the following characteristics will be considered ineligible:

               1. History of clinically significant renal, hepatic pulmonary, cardiovascular,
                  cerebrovascular, gastrointestinal, metabolic, hematological, endocrine,
                  urological, immunological, neurologic or psychiatric disorders or connective
                  tissue disease

               2. Positive for human immunodeficiency virus (HIV), Hepatitis B, or surface antigen
                  (HBsAg) or Hepatitis C antibody, tuberculosis (TB)

               3. Current drug or alcohol addiction

               4. History of clinically significant allergy of any kind

               5. Prior use of IL-12 or HemaMax

               6. Use of any approved or investigational biologic agents or vaccinations of any
                  kind in last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Siebers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gluzman-Poltorak Z, Vainstein V, Basile LA. Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure. Am J Hematol. 2014 Sep;89(9):868-73. doi: 10.1002/ajh.23770. Epub 2014 Jun 19.</citation>
    <PMID>24852354</PMID>
  </reference>
  <reference>
    <citation>Gluzman-Poltorak Z, Vainstein V, Basile LA. Association of Hematological Nadirs and Survival in a Nonhuman Primate Model of Hematopoietic Syndrome of Acute Radiation Syndrome. Radiat Res. 2015 Aug;184(2):226-30. Epub 2015 Jul 24.</citation>
    <PMID>26207689</PMID>
  </reference>
  <reference>
    <citation>Gluzman-Poltorak Z, Mendonca SR, Vainstein V, Kha H, Basile LA. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J Hematol Oncol. 2014 Apr 6;7:31. doi: 10.1186/1756-8722-7-31.</citation>
    <PMID>24708888</PMID>
  </reference>
  <reference>
    <citation>Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gill K, Mar V, Mendonca S, Miller JD, Tom J, Trinh A, Gallaher TK. HemaMax™, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One. 2012;7(2):e30434. doi: 10.1371/journal.pone.0030434. Epub 2012 Feb 24.</citation>
    <PMID>22383962</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HemaMax, NM-IL-12, HSARS, Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiation Injuries</mesh_term>
    <mesh_term>Acute Radiation Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

